Figure 5. LINC00160 promotes proliferation, migration and invasion of RCC. (A–D) LINC00160 expression was verified after transfection in ACHN and 786-O. (E–H) Proliferation assays revealed attenuated capabilities of ACHN (E) and 786-O (F) after knocking down LINC00160, and enhanced capabilities of ACHN (G) and 786-O (H) after overexpressing LINC00160. (I–L) Migration and invasion abilities of ACHN were weakened after knocking down LINC00160, and elevated after overexpressing LINC00160. (M–P) Migration and invasion abilities of 786-O were weakened after knocking down LINC00160, and elevated after overexpressing LINC00160. (Q–T) Wound healing assays revealed impaired capabilities of ACHN after knocking down LINC00160, and promoted capabilities after overexpressing LINC00160. (U–X) Wound healing assays revealed impaired capabilities of 786-O after knocking down LINC00160, and enhanced capabilities after overexpressing LINC00160. Each experiment was performed at least three times and data was represented as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. RCC, renal cell carcinoma.